What are you looking for?
The biosimilar aflibercept-ayyh was associated with stable vision in patients who switched from other anti-VEGF therapies and improved vision in treatment-naïve patients, according to a real-world analysis. The analysis included 1,000 consecutive eyes from 989 patients who received a total of 3,730 injections. Most eyes (91%) had previously been treated with another anti-VEGF therapy, while... ...
Switching to aflibercept 8 mg improved anatomical outcomes and reduced reliance on shorter treatment intervals, according to a study. However, researchers note...
Intravitreal aflibercept 8 mg administered with a loading phase followed by a treat-and-extend regimen improved visual acuity and reduced retinal and choroidal...
Patients with age-related macular degeneration (AMD) were found to have a higher risk of developing several mental health disorders, including depression, anxiety,...
A retrospective cross-sectional analysis examined seasonal patterns in new uveitis diagnoses across the United States. Investigators calculated incident uveitis cases by season within a baseline ophthalmology patient population. Cases were...
Existing preclinical and clinical evidence links GLP-1 receptor agonist use with differing effects across major eye diseases, showing a generally consistent association with reduced glaucoma incidence, mixed and nuanced findings...
Patients with diabetic macular edema (DME) treated with simultaneous intravitreal dexamethasone and aflibercept experienced sustained improvements in both visual acuity and retinal thickness over a 24-month follow-up period, with relatively...
Our most-read retinal coverage of 2025 highlights how long-term data and treatment innovations are influencing clinical practice. From 5-year real-world outcomes with aflibercept in central retinal vein occlusion to insights...
Intravitreal aflibercept (IVA) is effective for treating diabetic macular edema (DME) in eyes with or without prior pars plana vitrectomy (PPV), with similar visual and anatomical improvements and comparable treatment...
A new systematic review and meta-analysis highlights that anti-VEGF therapy leads to measurable improvements in quality of life for patients with diabetic macular edema (DME), though the overall gains remain...
Brolucizumab is associated with higher aqueous flare values than aflibercept in patients with neovascular age-related macular degeneration (nAMD), and these flare levels increase with age but are not influenced by...
Intravitreal aflibercept 2 mg provides sustained, long-term improvements in vision and retinal thickness for patients with treatment-naïve neovascular age-related macular degeneration (nAMD) over 36 months in real-world clinical practice, with...